Improving Outcomes for Psychiatric Patients with Metabolic Syndrome: An Evidence Based Quality Initiative
Metadata[+] Show full item record
Patients who are prescribed second generation antipsychotic medications are vulnerable and at an increased risk for developing metabolic syndrome (MetS). Metabolic syndrome is the development of obesity, hyperlipidemia, increased waist circumference, hypertension, and elevated blood glucose. Patients prescribed second generation antipsychotic medications who develop MetS experience shortened life expectancy by approximately10-30 years, with a 60% increase in mortality compared to the general population. Psychiatric providers are lax with regards to MetS screening, demonstrate lack of the essential knowledge required to screen for MetS, and have laissez faire attitudes and practice habits toward MetS screening. The purpose and goal of this quasi experimental evidence based quality initiative (EBQI) is to determine if education about and dissemination of a MetS screening tool will increase psychiatric providers screening rates and referral to primary care for metabolic syndrome treatment. Five psychiatric medication providers were provided with MetS screening education and screening tool dissemination as part of this EBQI project. The results showed significant increase in utilization of the MetS screening tool two months after education and screening tool dissemination, with further increases screening tool utilization four months after education and screening tool dissemination. Results indicate that further education is needed in referral of MetS screen positive patients to a primary care provider. As a result, increased MetS screening can have a positive impact on patient lifespan, quality of life, and decrease in healthcare expenditures annually.
Open Access (fully available)
Copyright retained by author